The Latest
It’s a big day on the COVID-19 vaccine front, with the FDA scheduled to review BioNTech/Pfizer Inc.’s mRNA vaccine later today.
Lagging behind the UK approval that came last week, there will be plenty of pressure on the FDA to give the approval.
COVID-19 cases across the U.S continues to rise as U.S states make their way through the winter months.
Approval would mean that BioNTech/Pfizer Inc. will be able to begin distributing vaccines as early as the weekend.
Unfortunately, supply chain issues have meant that vaccine production for the year will be as much as 50% lower than initially forecasted.